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Summary 
Introduction 
Leadless cardiac pacemakers (LCP) are self-contained intracardiac devices 
that are designed to have the same function as traditional cardiac pacemakers, 
but are miniaturized and can be implanted entirely inside the right ventricle 
of the heart. The expected benefit is the avoidance of complications associ-
ated with the placement of an external pulse generator in a surgical pocket 
in the chest and the transmission of impulses through transvenous leads re-
quired in conventional pacemakers.  
In the scope of this assessment are cardiac arrhythmias in adults for which 
single-chamber ventricular pacing (VVI) is indicated. First and foremost, these 
are patients with atrial fibrillation who require a pacemaker due to slow ven-
tricular response, but also patients with bradycardia due to atrioventricular 
block or sinus node disease might be considered if other pacing modes are not 
appropriate. 
The purpose of cardiac pacing is to provide an appropriate heart rate and 
heart response to reestablish effective circulation and more normal haemody-
namics that are compromised by a slow heart rate. Permanent pacemaker im-
plantation is further considered to alleviate symptoms associated with a brad-
yarrhythmia (e.g. dizziness, light-headedness, syncope, fatigue, poor exercise 
tolerance) or to prevent the possible worsening of the rhythm disturbance. 
 
Methods 
We assessed whether leadless pacemakers in comparison to conventional pace-
makers in patients with indications for right ventricle pacing are as effective 
and safe concerning exercise capacity and cardiovascular morbi-mortality, and 
more effective and safe concerning health-related quality of life and compli-
cations rate. Answering these research questions was based on a systematic lit-
erature search from different databases. The study selection, data extraction 
and assessing the methodological quality of the studies was performed by two 
review authors (AK, RE) independently from each other. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a 
recommendation: health related quality of life (HRQoL), exercise capacity. 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: serious adverse device effects (SADE), adverse device effects 
(ADE) and serious adverse events (SAE). 
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Results 
Available evidence 
We identified three prospective multi-centre single-arm trials with a total of 
633 participants analysed for efficacy endpoints and 1,284 participants ana-
lysed for safety endpoints. For the majority of the study participants, pacing 
was indicated due to atrial fibrillation with AV block. Other indications were 
sinus node dysfunction and AV block. Mean age of the study participants was 
76 years in all three studies. 
Clinical effectiveness 
None of the studies reported results on the outcomes defined as crucial to 
assess clinical effectiveness. 
Safety 
Overall mortality ranged from 3 to 5%; cardiac mortality was reported in two 
studies with 0.8% and 1%. Four deaths were reported as procedure-related.  
The rates of serious adverse device effects ranged between 4% and 6.5% in 
the three case series. In total, 20 patients experienced a cardiac injury. Six de-
vice dislodgements were reported with the Nanostim™ device, but none with 
the Micra™ TPS system. 
Other serious adverse events that were attributable either to the device or the 
procedure included vascular complications, arrhythmia during device implan-
tation and elevated pacing thresholds requiring retrieval and implantation of 
a new device. 
Upcoming evidence 
There are no randomised controlled trials currently planned or ongoing. Five 
single-arm studies are registered, that will analyse safety endpoints and pac-
ing thresholds. 
 
Discussion 
Leadless pacemakers are an emergent technology for which there are only pre-
liminary results available. The results indicate that leadless pacemaker can be 
successfully implanted and sustain a low pacing threshold for several months. 
The complications associated with leads and generators can be avoided, but 
procedural morbidity and mortality is a concern. Whether acute complications 
can be improved by training remains to be proven. Long-term issues such as 
battery longevity and device retrieval are not yet resolved. 
The available studies are non-randomised and there is no direct comparison 
of the benefit of LCP over contemporary single-chamber systems, so no de-
finitive conclusion can be drawn on the superiority or even non-inferiority of 
the new technology compared to standard therapy. There are no data on 
health-related quality of life of the patients. 
 
Conclusion 
The current evidence is not sufficient to prove, that the assessed technology 
Leadless pacemakers is as effective but more safe than conventional VVI pace-
makers. New study results will potentially influence the effect estimate con-
siderably. 
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Zusammenfassung 
Einleitung 
Sondenlose Herzschrittmacher sind miniaturiserte, in sich geschlossene Herz-
schrittmacher, die dieselben Funktionen wie herkömmliche Herzschrittma-
cher erfüllen sollen, aber zur Gänze in die rechte Herzkammer implantiert 
werden können. Daraus erwartet man den Vorteil, dass Komplikationen im 
Zusammenhang mit dem externen Generator in einer subkutane Hauttasche 
und den transvenösen Sonden für die Impulsübertragung, die bei konventi-
nellen Herzschrittmachern notwendig sind, vermieden werden.  
Gegenstand dieses Berichts sind kardiale Arrhythmien, die eine Indikation 
für einen Einkammerschrittmacher in der rechten Herzkammer (VVI Schritt-
macher) darstellen. Dabei handelt es sich in erster Linie um PatientInnen mit 
bradykardem, permanenten Vorhofflimmern, bei denen VVI-Schrittmacher 
zur Überbrückung der bradykarden Phasen implantiert werden. Auch bei Pa-
tientInnen mit Bradykardien aufgrund eines Sick-Sinus-Syndroms oder atri-
ventrikulärem Blocks kann ein VVI Schrittmacher indiziert sein, wenn ande-
re Schrittmachersysteme nicht in Frage kommen. 
Ziel der Schrittmachertherapie ist die Stabilisierung des Herzrhythmus und 
damit die Wiederherstellung eines effektiven Kreislaufs und normaler Hämo-
dynamik, die durch die Bradykardie beeinträchtigt wurden. Damit sollen die 
Symptome, die mit Bradyarrhythmien einhergehen (z. B. Schwindel, Ohn-
macht, Müdigkeit, niedrige Belastungsfähigkeit) verringert werden. 
 
Methoden 
Wir untersuchten, ob sondenlose Herzschrittmacher im Vergleich zu konven-
tionellen Herzschrittmachern in PatientInnen mit Indikationen für VVI HSM 
ebenso wirksam und sicher hinsichtlich der Endpunkte Belastungsfähigkeit 
und kardialer Morbimortalität und wirksamer und sicherer hinsichtlich der 
Endpunkte gesundheitsbezogene Lebensqualität und Komplikationsrate sind. 
Um diese Forschungsfrage zu beantworten, wurde eine systematische Litera-
tursuche in verschiedenen Datenbanken durchgeführt. Die Studienauswahl, 
Datenextraktion sowie die Bewertung der methodischen Qualität der Studie 
wurde unabhängig voneinander von zwei AutorInnen (AK, RE) durchgeführt.  
Wirksamkeit 
Die folgenden Endpunkte wurden für die Bewertung der Wirksamkeit als 
entscheidend definiert: HRQoL, Belastungsfähigkeit. 
Sicherheit 
Die folgenden Endpunkte wurden für die Bewertung der Sicherheit als ent-
scheidend definiert: schwere produktbezogene unerwünschte Ereignisse  
(SADE), produktbezogene unerwünschte Ereignisse (ADE) und schwere un-
erwünschte Ereignisse (SAE). 
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Ergebnisse 
Verfügbare Evidenz 
Wir identifizierten drei prospektive multizentrische Einzelarmstudien mit 
insgesamt 633 TeilnehmerInnen, die für Wirksamkeitsendpunkte analysiert 
wurden (Wirksamkeitskohorten) und insgesamt 1.284 TeilnehmerInnen, die 
für Sicherheitsendpunkte analysiert wurden. Bei der Mehrheit der Teilneh-
merInnen war der Herzschrittmacher aufgrund von Vorhofflimmern mit AV 
Block indiziert. Andere Indikationen waren Sick-Sinus-Syndrom und AV 
Block. Das Durchschnittsalter lag bei 76 Jahren in allen drei Studien. 
Wirksamkeit 
Keine der eingeschlossenen Studien berichtete Ergebnisse zu klinischen Wirk-
samkeitsendpunkten. 
Sicherheit 
Die Gesamtmortalität lag bei 3 bis 5 %; die kardiale Mortalität bei 0,8 bzw. 
1 % (Daten aus zwei Studien). Es wurden insgesamt vier Todesfälle berich-
tet, die als prozedur-bezogen eingestuft wurden.  
Schwere produktbezogenen Ereignisse wurden in 4 bis 6,5 % der Teilnehme-
rInnen berichtet. Insgesamt gab es 20 Fälle von Herzverletzungen. Nur in den 
Nanostim™ Studien wurden – insgesamt 6 – Implantatsablösungen berichtet.  
Andere schwere unerwünschte Ereignisse, die entweder im Zusammenhang 
mit der Prozedur oder dem Gerät auftraten, inkludierten vaskuläre Kompli-
kationen, Arrhythmien während der Implantation und erhöhte pacing thres-
holds, die die Entfernung oder den Tausch des Geräts erforderten.  
Laufende Studien 
Es sind keine randomisierten kontrollierten Studien geplant oder laufend. 
Es sind fünf Einzelarmstudien registriert, die Sicherheitsendpunkte und pa-
cing thresholds als primäre Endpunkte analysieren werden.  
 
Diskussion 
Sondenlose Herzschrittmacher sind eine aufkommende Technologie, für die 
erst vorläufige Ergebnisse verfügbar sind. Die Studien zeigen, dass sonden-
lose Schrittmachr erfolgreich implantiert werden können und therapeutisch 
wirksame thresholds für mehrere Monate erhalten können. Zwar fallen ge-
nerator- und sonden-assoziierte Komplikationen weg, es bestehen jedoch Be-
denken hinsichtlich der prozeduralen Morbidität und Mortalität. Ob diese 
durch geplante Trainingsmaßnahmen reduziert werden können, bleibt noch 
zu beweisen. Längerfristige Probleme im Zusammenhang mit Batteriedauer 
und eventuell notwendiger Gerätexplantation sind vorerst ungeklärt.  
Die vorhandenen Studien sind nicht-randomisiert und es gibt keinen direkten 
Vergleich zwischen sondenlosen HSM und konventionellen Geräten. Wesent-
liche Endpunkte etwa zur Lebensqualität wurden noch gar nicht untersucht.  
 
Schlußfolgerung 
Eine abschließende Beurteilung ist aufgrund fehlender Daten zu wesentlichen 
Endpunkten nicht möglich. 
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1 Scope 
1.1 PICO question 
Are leadless pacemakers in comparison to conventional pacemakers in patients 
with indications for right ventricle pacing as effective and safe concerning car-
diovascular morbidity and mortality, exercise capacity, and more effective and 
safe concerning patient-related quality of life and complication rate? 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1-1. 
Table 1-1: Inclusion criteria 
Population First line treatment of patients with indications for single-chamber ventricular 
pacemakers [1, 2] 
 Patients with chronic atrial fibrillation (AF; ICD-10 I.48) who require a pacemaker 
for persistent or intermittent bradycardia due to slow ventricular response 
(atrioventricular (AV) block, ICD-10 I.44) 
 Patients with persistent or intermittent bradycardia due to AV block or 
symptomatic sinus node disease (SND, ICD-10 I.49.5)1 
Contraindications:  
 Patients requiring long-term pacing exceeding estimated device longevity  
(NB. children) 
 Patients with indications for atrial single-chamber pacemakers or dual-chamber 
pacemakers or with indications for cardiac resynchronisaton therapy  
MESH term: Arrhythmias, Cardiac [C14.280.067] and Arrhythmias, Cardiac [C23.550.073] 
Intervention Leadless self-contained and fully implantable VVI(R) pacemaker 
Setting: Vascular surgery, Interventional cardiology; specialist hospital, general hospital 
Products:  
Micra™ TPS, Medtronic Inc (available in Austria) 
Nanostim™, St. Jude Medical (available in Austria by end of 2016) 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Control Conventional VVI(R) pacemaker 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Outcomes  
Efficacy Cardiovascular mortality 
Cardiovascular morbidity  
Patient related quality of life 
Exercise capacity 
Pacing performance 
Safety Complication rate 
 
                                                             
1
 Only in specific instances, where other pacing modes (dual-pacing, atrial pacing) 
are not recommended  
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
Leadless pacemakers for right ventricle pacing 
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Study design  
Efficacy Randomised controlled trials (Non-inferiority)2 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case series or registries with >100 patients 
ESC – European Society of Cardiology; AV – atrioventricular; TPS – transcatheter pacing system;  
VVIR – Single-chamber ventricular pacing with response modulation 
 
 
                                                             
2
 Randomised controlled trials comparing leadless pacemakers with traditional pace-
makers are desired, since they are appropriate (adequate number of patients, inter-
vention not urgent) and ethical (clinical equipoise, patients able to give consent) and 
necessary due to small plausible effect sizes. Blinding of operators and patients how-
ever is not possible, and placebo-controlled trials would be unethical due to the avail-
ability of an effective treatment. 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What are leadless pacemakers and conventional single-chamber ventricular pacemakers? 
A0020 For which indications have leadless pacemakers received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of leadless pacemakers in relation to conventional single-chamber 
ventricular pacemakers? 
B0003 What is the phase of development and implementation of leadless pacemakers and 
conventional single-chamber ventricular pacemakers? 
B0004 Who administers leadless pacemakers and conventional single-chamber ventricular 
pacemakers and in what context and level of care are they provided? 
B0008 What kind of special premises are needed to use leadless pacemakers and conventional  
single-chamber ventricular pacemakers? 
B0009 What supplies are needed to use leadless pacemakers and conventional single-chamber 
ventricular pacemakers? 
A0020 What is the marketing authorisation status of leadless pacemakers? 
A0021 What is the reimbursement status of leadless pacemakers? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes are leadless pacemakers used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for cardiac arrhythmias? 
A0004 What is the natural course of cardiac arrhythmias? 
A0005 What is the symptoms and the burden of disease for the patients with cardiac arrhythmias? 
A0006 What are the consequences of cardiac arrhythmias for the society? 
A0024 How are cardiac arrhythmias currently diagnosed according to published guidelines and in practice? 
A0025 How are cardiac arrhythmias currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are leadless pacemakers utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How do leadless pacemakers affect symptoms and findings (severity, frequency) of the disease 
or health condition? 
D0006 How do leadless pacemakers affect progression (or recurrence) of the disease or health condition? 
D0011 What is the effect of leadless pacemakers on patients’ body functions? 
D0016 How does the use of leadless pacemakers affect activities of daily living? 
D0012 What is the effect of leadless pacemakers on generic health-related quality of life? 
D0013 What is the effect of leadless pacemakers on disease-specific quality of life? 
D0017 Was the use of leadless pacemakers worthwhile? 
Leadless pacemakers for right ventricle pacing 
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Safety 
Element ID Research question 
D0001 What is the expected beneficial effect of leadless pacemakers on mortality? 
D0003 What is the effect of leadless pacemakers on the mortality due to causes other than the 
target disease? 
C0008 How safe are leadless pacemakers in comparison to conventional single-chamber 
ventricular pacemakers? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the 
use of the technology? 
C0007 Are leadless pacemakers and conventional single-chamber ventricular pacemakers 
associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases for Health 
Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases for Health 
Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
 National registries (Statistik Austria) 
 Handsearch for management guidelines 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on 09.12.2015 in the following 
databases:  
 Medline via Ovid 
 Embase  
 Pubmed 
 CRD (DARE, NHS-EED, HTA) 
 Cochrane library 
After deduplication, overall 144 citations were included. The specific search 
strategy employed can be found in the appendix.  
Quellen 
systematische 
Literatursuche in  
fünf Datenbanken  
Methods 
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Manufacturers from the two available products (Medtronic, St. JudeMedical) 
submitted 8 publications of which 0 new citations were identified.  
No additional references were found by handsearch. 
 
 
2.4 Flow chart of study selection 
Overall 144 hits were identified. The references were screened by two inde-
pendent researchers (AK, RE) and in case of disagreement a third researcher 
was involved to solve the differences. The selection process is displayed in 
Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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References included in 
qualitative synthesis 
(n=5) 
 RCTs (n=0) 
 NRCTs (n=0) 
 Case-series (n=5) 
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2.5 Analysis 
The information was retrieved from the sources identified. No further analysis 
was performed. 
Quality was assessed using the EUnetHTA checklist for case series (see Table 
A-2).  
 
 
2.6 Synthesis 
The questions were answered in plain text format with reference to GRADE 
evidence tables that are included in Table 7-1. 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What are leadless pacemakers and  
conventional single-chamber ventricular pacemakers? 
Leadless cardiac pacemakers (LCP) are self-contained intracardiac devices 
that are designed to have the same function as traditional cardiac pacemak-
ers, but are miniaturized and can be implanted entirely inside the right ven-
tricle of the heart via a steerable catheter [3]. In conventional pacemakers, a 
separate pulse generator containing the battery and the machinery for sens-
ing and timing of the electrical impulses is placed in a (most commonly) pec-
toral subcutaneous pocket. The electrical impulses are delivered from the gen-
erator to the heart through one or more transvenous leads, depending on the 
desired pacing mode [4]. The majority of conventional pacemakers are capa-
ble of several pacing modes, such as single-chamber ventricular or atrial pac-
ing, or dual chamber pacing. The current generation of single-unit LCP can 
only be used for single-chamber pacing, specifically right ventricular pacing 
[4]. Pacing modes are classified according to a standardised code (Table 3-1).  
This limitation does not apply to multi-component leadless pacing systems 
using ultrasound or induction to deliver electrical impulses from a separate 
generator to the heart; these systems are however not the subject of the pre-
sent report, which is restricted to fully self-contained leadless pacemakers.  
Table 3-1: Revised NBG code for pacing nomenclature [5] 
Position I II III IV V 
Category 
Chamber(s) 
paced 
Chamber(s) 
sensed 
Response  
to sensing 
Rate 
modulation 
Multisite  
pacing 
 0 = None 
A = Atrium 
V = Ventricle 
D = Dual (A+V) 
0 = None 
A = Atrium 
V = Ventricle 
D = Dual (A+V) 
0 = None 
T = Triggered 
I = Inhibited 
D = Dual (T+I) 
0 = None 
R = Rate 
modulation 
0 = None 
A = Atrium 
V = Ventricle 
D = Dual (A+V) 
 
Marketed products 
Currently two leadless pacing systems are available: the Nanostim™ leadless 
cardiac pacemaker and the Micra™ transcatheter pacing system (TPS) (see 
Table 3-2 for a comparison of the specifications). Both have a volume of up 
to 1cm³ and thus are approximately ten times smaller than conventional sin-
gle-chamber ventricular (VVI) pacemakers [3, 4]. The devices have an esti-
mated battery longevity of approximately ten years, which is comparable to 
conventional pacemakers [3, 4]. In theory, both systems offer a device retriev-
al option, allowing repositioning or retrieval of the devices following implan-
tation [3, 4]. There are no data, however, on the removal of chronic implant-
ed systems [3]. Main differences between the systems are related to the fixa-
tion mechanism: Nanostim™ LCP uses a screw-in helix and a secondary fix-
ation mechanism of three nylon tines, whereas the Micra™ TPS uses four self-
expanding nitinol tines [4]. 
miniaturisierte, 
vollständig 
implantierbare 
Herzschrittmacher 
(HSM) 
zwei Produkte: 
Nanostim™ leadless 
cardiac pacemaker und 
Micra ™ transcatheter 
pacing system 
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Table 3-2: Specifications of fully self-contained leadless cardiac pacemakers 
 Nanostim™  
leadless cardiac pacemaker 
Micra™  
transcatheter pacing system 
Manufacturer St. Jude Medical Medtronic 
Volume (cm³) 1 0.8 
Size (h x w), maximum thickness, mm 42 x 5.99 25.9 x 6.7 
Fixation mechanism Screw-in helix (+ nylon tines) Self-expanding nitinol tines 
Pacing mode VVI(R) VVI(R) 
Battery longevity (years) 9.8 10 
Device retrieval option Yes Yes 
CE mark Yes, October 2013 Yes, April 2015 
FDA approval No, investigational device No, investigational device 
 
According to the manufacturer’s website [6] Nanostim™ leadless pacemaker 
is indicated for: 
 Chronic atrial fibrillation with 2 or 3° atrioventricular block (AV)  
or bifascicular bundle branch block (BBB), 
 Normal sinus rhythm with 2 or 3° AV or BBB block and a low level  
of physical activity or short expected lifespan, or 
 Sinus bradycardia with infrequent pauses or unexplained syncope 
with electrophysiological findings.  
According to the product manual [7] the Micra™ Transcatheter Pacing Sys-
tem is indicated for use to improve cardiac output, prevent symptoms, or pro-
tect against arrhythmias related to cardiac impulse formation or conduction 
disorders. The device is indicated for use in patients who are experiencing ex-
ercise intolerance or exercise restrictions related to an arrhythmia. The device 
is designed to be used only in the right ventricle.  
B0002 – What is the claimed benefit of leadless pacemakers  
in relation to conventional single-chamber ventricular pacemakers? 
In contrast to traditional pacemakers, leadless pacemakers do not require the 
placement of an external pulse generator in a surgical pocket in the chest and 
the transmission of impulses through transvenous leads. The claimed benefit 
is accordingly the avoidance of complications associated with these two com-
ponents of traditional pacemaker implantation. The subcutanous pocket has a 
potential for local complications such as skin erosion, pocket haematoma and 
pocket infection. In up to six out of ten patients, it causes reduced mobility in 
the shoulder region where the pulse generator is placed [8]. Lead-related com-
plications include venous obstructions, insulation breaks, lead dislodgements, 
electrical malfunction lead fractures and infection. Of particular concern are 
infections requiring lead extraction, as the procedure is associated with a high 
risk of complications [9, 10]. 
Additional benefits are expected with regards to shorter procedure and re-
covery times and a better quality of life as a result of the maintenance of 
shoulder mobility and the absence of a lump or scar. 
Indikationen  
wie für Einkammer-
schrittmacher 
angegebener Nutzen: 
Vermeidung von 
Komplikationen 
verursacht durch 
externe Generatoren 
und Sonden 
kürzere 
Behandlunsgdauer, 
verbesserte 
Lebensqualität 
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B0003 – What is the phase of development and implementation  
of leadless pacemakers and conventional single-chamber ventricular 
pacemakers? 
Conventional single-chamber ventricular pacemakers are a well-established 
standard technique [1].  
Leadless pacemakers are an emerging technology, not yet established in use. 
The technology represents a modification of the existing pacemaker technology.  
 
Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers leadless pacemakers and conventional  
single-chamber ventricular pacemakers and in what context and level  
of care are they provided? 
B0008 – What kind of special premises are needed to use leadless 
pacemakers and conventional single-chamber ventricular pacemakers? 
B0009 – What supplies are needed to use leadless pacemakers and 
conventional single-chamber ventricular pacemakers? 
Both LCP and traditional pacemakers are provided in specialised centres with 
interventional cardiology in the cardiac catheterization, laboratory sedative 
medication and local anaesthesia. LCP implantation further requires fluor-
oscopy to guide positioning of the device. 
Setting and staff required for LCP implantation do not differ from tradition-
al pacemaker procedures. However, given the novel implantation method for 
this device, additional training for medical specialists who implant LCP will 
be required.  
 
Regulatory & reimbursement status  
A0020 – What is the marketing authorisation status  
of leadless pacemakers? 
A0021 – what is the reimbursement status of leadless pacemakers? 
Nanostim™ LCP 
Europe: In October 2013, St. Jude Medical received CE mark approval (for 
European commercialization) to market the Nanostim™ leadless pacemaker 
in the European Union (EU). According to the EU registry, the Leadless Ob-
servational Study (NCT02051972) is ongoing in Europe with sites in the Unit-
ed Kingdom, Germany, Italy, the Czech Republic, France, Spain, and the 
Netherlands with a planned enrolment of 1,000 patients and follow-up for 5 
years. Data from 300 patients with 6 months of follow-up will be used to meet 
the post market clinical follow-up requirements for CE marking.  
The United States, Canada and Australia: A trial designed to investigate Na-
nostim™ for the United States Food and Drug Administration (FDA) approv-
al was initiated in February 2014 (NCT02030418). Sites from the USA, Can-
ada and Australia participated in the LEADLESS II study. The enrolments 
(667 patients) were completed in 2015 and the pre-specified safety/effective-
ness endpoints were met. FDA has provided approval to enrol up to 900 ad-
ditional patients in the continued access phase and enrolments are underway. 
The device has not yet been approved by FDA, Health Canada or TGA (Aus-
tralia). FDA approval of the device is sought in 2016. 
konventionelle HSM gut 
etablierte, sondenlose 
HSM aufkommende 
Technologie 
Setting: interventionelle 
Kardiologie 
spezielles Training für 
LCP Implantation 
notwendig 
Nanostim™:  
CE Mark seit  
Oktober 2013 
 
FDA Zulassung  
für 2016 angestrebt 
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Japan: Enrolments in the Leadless Japan pre-market study are underway and 
the plan is to enrol 22 Japanese patients in the study to meet the primary end-
point analysis. (Information on regulatory status was submitted by the man-
ufacturer) 
Micra™ TPS 
Medtronic received CE mark for Micra™ TPS in 2015, and the US FDA ap-
proval is sought in 2017-2018. An FDA approval study on Micra™ TPS was 
initiated in November 2013 (NCT02004873). (Information on regulatory sta-
tus was submitted by the manufacturer) 
Leadless pacemakers are currently reimbursed in Austria via the MEL code 
DE080 Implantation of a single-chamber pacemaker. 
 
Micra™  
CE Mark seit 2015 
 
FDA Zulassung für  
2017-2018 angestrebt 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
are leadless pacemakers used? 
Leadless pacemakers are developed as alternatives for traditional permanent 
cardiac pacemakers for the treatment of a variety of cardiac arrhythmias. The 
natural pacemaker of the heart is the sinus node located in the right atrium. 
It generates around 70 regular electrical impulses per minute (at rest), that 
are conducted across the rest of the heart. This triggers contraction of the 
atriums followed by the contraction of the ventricles allowing the blood flow. 
Cardiac bradyarrhythmias are mainly due to either the incapacity of the sinus 
node to produce enough number of impulses per minute (sinus node disease) 
or the disturbance in atrioventricular (AV) conduction.  
Atrial fibrillation is an abnormal heart rhythm characterized by rapid and 
irregular beating, but can be associated with bradycardia. The principal rea-
son to place a pacemaker in a patient with atrial fibrillation (AF) is to treat 
symptomatic bradycardia. Pacing has not been shown to prevent the devel-
opment of AF. 
The purpose of cardiac pacing is to provide an appropriate heart rate and 
heart response to reestablish effective circulation and more normal haemo-
dynamics that are compromised by a slow heart rate (bradycardia or brady-
arrhythmia: <60 beats per minute). Permanent pacemaker implantation is 
further considered to alleviate symptoms associated with a bradyarrhythmia 
(e.g. dizziness, light-headedness, syncope, fatigue, poor exercise tolerance) 
or to prevent the possible worsening of the rhythm disturbance [11]. 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
In the scope of this assessment are cardiac arrhythmias in adults for which 
single-chamber ventricular pacing (VVI) is indicated. Guidelines for implan-
tation of permanent pacemakers have been established by the American Col-
lege of Cardiology, the American Heart Association and the Heart Rhythm 
Society (ACC/AHA/HRS) [2] and by the European Society of Cardiology (ESC) 
[1]. 
VVI pacing mode is the method of choice for patients with chronic atrial fi-
brillation (AF; ICD-10 I.44) who require a pacemaker due to slow ventricular 
response (atrioventricular (AV) block, Class I recommendation [1]).  
This pacing mode may be considered for patients with AV block, even in the 
absence of AF, on an individual basis, but in general is not considered the 
first choice [1].  
In patients with sinus node disease as well as in patients with atrial fibrilla-
tion, pacing is only indicated if bradycardia causes symptoms. Dual-chamber 
pacing is recommended over VVI pacing [1]. 
LCP werden zur 
Behandlung kardialer 
Arrhythmien eingesetzt 
 
 
 
Ursachen für 
Bradycardia: 
- Störung des 
Sinusknoten 
- Blockierung der 
Erregungsüberleitung 
auf den AV-Knoten 
Fokus dieses Berichts: 
Indikationen für 
Einkammerschrittmacher 
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A0003 – What are the known risk factors for cardiac arrhythmias? 
Bradyarrhythmias requiring cardiac pacing can be caused by a variety  
of aetiologies [1]. Intrinsic causes are:  
 Idiopathic (ageing) degeneration 
 Ischaemic heart disease 
 Infiltrative diseases (e.g. sarcoidosis, amyloidosis, haemochromatosis) 
 Collagen vascular diseases (e.g. systemic lupus erythematosus,  
rheumatoid arthritis, scleroderma) 
 Congenital diseases, including sinus node and AV node disease 
 Infective diseases (e.g. Lyme disease) 
 Rare genetic diseases  
 Surgical trauma: valve replacement (including percutaneous aortic 
replacement), heart transplantation 
 Intended or unintended AV block due to catheter ablation procedure 
Extrinsic causes are:  
 Physical training (sports) 
 Vagal reflex: vasovagal, situational, carotid sinus syndrome 
 Idiopathic paroxysmal AV block 
 (Adverse) drug effects 
 Cocaine abuse and other recreational drugs 
 Electrolyte imbalance: hypokalaemia, hyperkalaemia 
 Metabolic disorders: hypothyroidism, hypothermia, anorexia nervosa 
 Neurological disorders 
 Obstructive sleep apnoea 
A0004 – What is the natural course of cardiac arrhythmias? 
The natural history and the role of pacing differ depending on the type of 
bradyarrhythmia.  
In patients with untreated AV block, death can occur due to heart failure sec-
ondary to low cardiac output or to sudden cardiac death caused by prolonged 
asystole or bradycardia-triggered ventricular tachyarrhythmia. Several obser-
vational studies indicate that pacing prevents recurrence of syncope and im-
proves survival [1].  
Total survival and the risk of sudden cardiac death of patients with sinus node 
disease (SND, also sick sinus syndrome) are similar to the general population 
[12, 13].There is a strong consensus that patients with SND will benefit from 
cardiac pacing for symptom relief (only) [1].  
 
  
Bradyarrhythmien 
können eine Vielzahl  
an Ätiologien  
zugrunde liegen 
Unterscheidung 
zwischen extrinsischen 
und intrinsischen 
Faktoren 
AV Block: erhöhtes 
Sterberisiko aufgrund 
von Herzversagen 
SND: kein erhöhtes 
Sterberisiko 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with  
cardiac arrhythmias? 
Symptoms are present if bradycardia is severe enough to compromise blood 
flow: they may comprise fatigue, dizziness, syncope (fainting), dyspnoea, chest 
pain, weakness and a reduced exercise capacity.  
Major complications associated with the implantation of a single-chamber RV 
pacemaker include lead-related re-interventions, local infections requiring re-
intervention, device-related systemic infections, endocarditis, pneumothorax 
requiring drainage, cardiac perforation, pocket revisions because of pain, gen-
erator-lead interface problems requiring re-intervention, haematomas requir-
ing re-intervention, deep venous thrombosis, Twiddler’s syndrome, wound re-
visions, stroke, myocardial infarctions, and procedure-related deaths. Minor 
complications include haematomas resulting in a prolonged hospital stay, 
hospital re-admissions, additional out-patient visits, wound infections treat-
ed with antibiotics, conservatively treated pneumothorax, and lead dislodge-
ments without re-intervention [9, 14].  
Up to 6% of patients experience major complications within the first six 
months following implantation of cardiac electronic devices (all types), with 
lead-related re-intervention being the single most common complication, fol-
lowed by infections, pneumothorax and cardiac perforation. For single-chamber 
pacemakers, this risk is however significantly lower, with 3.3% experiencing 
any major complication [14]. Also the risk of lead complications is lower for 
single chamber right ventricular pacemakers compared to other pacemaker 
types [10]. 
A0006 – What are the consequences of cardiac arrhythmias  
for the society? 
The prevalence of indications requiring single-chamber pacemaker implan-
tation in Austria is unclear. In 2011 over 116,000 patients with cardiac ar-
rhythmias were recorded [15]. Each year there are about 6,000 pacemaker im-
plantations in Austria, of which approximately one third are single-chamber 
pacemakers [16, 17].  
 
Current clinical management of the disease or health condition 
A0024 – How are cardiac arrhythmias currently diagnosed  
according to published guidelines and in practice? 
There is no defined heart rate below which treatment is indicated. When de-
ciding on the need for cardiac pacing, the correlation between symptoms and 
bradyarrhythmia needs to be established. The diagnosis of bradyarrhythmia 
is usually made from a standard electrocardiogram (ECG) when persistent, 
and from a standard ECG or more prolonged ECG recordings (ambulatory 
monitoring or implantable loop recorder) when intermittent. Provocative test-
ing or an electrophysiological study may be required when a bradycardia is 
suspected but not documented. This strategy is based on the assumption that 
provoked abnormalities will have the same mechanism as spontaneous epi-
sodes. (Long-term) ECG monitoring has the advantage of high diagnostic ac-
curacy, whereas provocative testing is faster, but more prone to misdiagnosis 
[1]. 
Symptome bei 
eingeschränktem 
Blutfluss 
schwere Komplikationen 
sind u. a. erforderliche 
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Infektionen; 
Herzperforation, 
Pneumothorax 
ca. 6.000 
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pro Jahr in Ö 
Diagnose über  
Langzeit-EKG oder 
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A0025 – How are cardiac arrhythmias currently managed according  
to published guidelines and in practice? 
A0007 – What is the target population in this assessment? 
A0023 – How many people belong to the target population?  
Leadless pacemakers are intended to be used as replacement for conventional 
single-chamber right ventricular pacemakers. The target population consists 
of the patients in which this pacing mode is indicated. There are no data 
available on the number of patients belonging to the target population. Ap-
proximately 2,000 patients receive a single-chamber pacemaker each year in 
Austria [16, 17].  
The decision regarding pacemaker implantation and choice of pacing mode 
is based on three clinical factors: the location of the conduction abnormality, 
the presence of symptoms and their association with the bradyarrhythmia, and 
the absence of a reversible cause (Figure 4-1). 
 
SND Sinus node disease; AV atrioventricular; AF Atrial fibrillation; AVM AV delay management.  
For nomenclature of pacing modes see Table 3-1: Revised NBG code for pacing nomenclature [5] 
Figure 4-1: Choice of the pacing mode (ESC guidelines, [1]) 
VVI pacing mode is the method of choice for patients with chronic atrial fi-
brillation (AF; ICD-10 I.44) who require a pacemaker due to slow ventricular 
response (atrioventricular (AV) block, Class I recommendation [1]).  
Atrioventricular (AV) block is defined as a delay or interruption in the trans-
mission of an impulse from the atria to the ventricles due to an anatomical 
or functional impairment in the conduction system. The conduction can be 
delayed, intermittent, or absent. The commonly used classification includes 
first degree (slowed conduction without loss of atrioventricular synchrony), 
second degree (intermittent loss of atrioventricular conduction, often in a reg-
ular pattern, e.g., 2:1, 3:2, or higher degrees of block), and third degree or 
complete AV block [11].  
sondenlose 
Herzschrittmacher  
als Alternative zu 
herkömmlichen  
VVI Schrittmachern 
VVI Methode der Wahl 
für PatientInnen mit 
chronischem 
Vorhofflimmern  
und AV Block 
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In patients with acquired AV block (but no AF) or sinus node disease (SND), 
the condition can be managed with either a single or dual chamber pacemak-
er. Dual-chamber pacing is recommended over single chamber ventricular 
pacing for avoiding pacemaker syndrome, lowering the risk of developing AF 
and improving quality of life (class IIa recommendation, [1]). However, the 
decision should take into account the increased complication risk and costs 
of dual-chamber pacing.  
Sinus bradycardia (SB) is a rhythm in which fewer impulses than the normal 
number arise from the sinoatrial node. It is caused by a primary sinus node 
dysfunction or by other conditions (drugs, acute myocardial infarction, ob-
structive sleep apnoea, etc.). In general, SB is only an indication for pacing if 
bradycardia is symptomatic, if the symptoms can be attributed to SB and if a 
reversible cause can be excluded. Dual-chamber pacing is the pacing mode of 
first choice and unnecessary right ventricular pacing should be avoided since 
it may cause AF and deterioration of heart failure. In the subset of patients 
with SND in whom AV conduction is intact, single-chamber is feasible (AAI 
mode); atrial pacemakers are recommended over ventricular pacemakers [1]. 
 
Target population 
A0011 – How much are leadless pacemakers utilised? 
Estimates of the expected yearly utilisation of leadless pacemaker vary from 
270 to 2,400 implantations in Austria (information from the submitting hos-
pitals). 
 
nicht die erste Wahl  
für PatientInnen mit  
AV Block ohne 
Vorhofflimmern 
VVI nicht erste Wahl  
für SND ohne AV Block, 
sollte vermieden werden 
geschätzter Bedarf 
zwischen 270 und 2.400 
Implantationen 
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5 Clinical effectiveness 
5.1 Outcomes 
The implantation of pacemakers serves the primary purpose to alleviate symp-
toms associated with a slow heart rhythm. The pacemaker does not treat atri-
al fibrillation, the main indication for single chamber ventricular pacing, it-
self. Recent reports indicate that prognosis of bradycardia pacemaker recipi-
ents are mainly determined by comorbid diseases and a bradycardia pacing 
indication as such does not influence survival [18]. 
The following outcomes were therefore defined as crucial to derive  
a recommendation: 
 Health related quality of life (HRQoL) 
 Exercise capacity 
For the assessment of HRQoL, Aquarel is a QoL questionnaire specifically 
designed for patients with PM, which must be used with the SF-36 generic 
questionnaire [19-21]. Aquarel consists of 20 questions divided into three do-
mains: chest discomfort (corresponding to questions 1 to 6, about chest pain, 
and questions 11 and 12, about dyspnea at rest), arrhythmia (corresponding 
to questions 13 to 17), and dyspnea on exertion (corresponding to questions 
7 to 10, about dyspnea on exertion, and questions 18 to 20, about fatigue). 
Exercise capacity was chosen as a measure of functional capacity. The assess-
ment is typically performed on a motorised treadmill or a stationary cycle er-
gometer and exercise duration, maximal exercise capacity and maximal oxy-
gen uptake are measured [22]. 
Pacing performance was the primary efficacy endpoint in all studies identi-
fied, however this endpoint is not a clinical endpoint and hence was not de-
fined as crucial to derive a recommendation. 
 
 
5.2 Included studies 
There are no comparative studies to assess the effectiveness of leadless pace-
makers. We identified five references to three prospective multi-centre single 
arm studies that reported the performance of leadless pacemakers [23-27] in 
a total of 633 participants (efficacy cohorts). All studies were sponsored by 
device manufacturers. Study characteristics and results of included studies 
are displayed in Table A-1. 
All three studies included patients with indications for VVI pacing, with a 
restriction on non-pacemaker dependent patients in one study [23, 25]. For 
the majority of the study participants, pacing was indicated due to atrial fi-
brillation with AV block (range 56-67%). Other indications were sinus node 
dysfunction (range 15-35%) and AV block (range 8.7-18%). For the latter two 
indications, reasons for the selection of VVI pacing mode were the expecta-
tion of only infrequent need for pacing, advanced age of the patient, patient 
preference, conditions that precluded implantation of a transvenous pacemak-
er system or significant comorbidities.  
Wirksamkeit – 
entscheidungsrelevante 
Endpunkte: 
Lebensqualität, 
Belastungsfähigkeit 
3 prospektive 
Einzelarmstudien mit 
633TeilnehmerInnen 
(Wirksamkeitskohorte) 
verschiedene 
Indikationen für  
VVI Herzschrittmacher 
 
 
hohes Alter, viele 
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Mean age of the study participants was 76 years in all three studies. The study 
populations were predominantly male (range 59-67%). Comorbidities were 
frequent, with almost 80% of the participants suffering from hypertension.  
However none reported any of the outcomes defined as crucial to derive a 
recommendation. 
 
 
5.3 Results 
Morbidity 
D0005 – How do leadless pacemakers affect symptoms and  
findings (severity, frequency) of cardiac arrhythmias? 
None of the studies reported results on symptoms associated with cardiac ar-
rhythmias.  
D0006 – How do leadless pacemakers affect progression (or recurrence) 
of cardiac arrhythmias? 
None of the studies reported results on progression of cardiac arrhythmias.  
None of the studies reported pacing-induced arrhythmias. 
 
Function 
D0011 – What is the effect of leadless pacemakers  
on patients’ body functions? 
None of the studies reported results on patient’s body functions.  
D0016 – How does the use of leadless pacemakers  
affect activities of daily living? 
None of the studies reported results on exercise capacity.  
 
Health-related quality of life 
D0012 – What is the effect of leadless pacemakers  
on generic health-related quality of life? 
D0013 – What is the effect of leadless pacemakers  
on disease-specific quality of life? 
None of the studies reported results on health-related quality of life.  
 
Patient satisfaction 
D0017 – Was the use of leadless pacemakers worthwhile? 
None of the studies reported results on patient satisfaction. 
 
keine Ergebnisse  
zu klinischen 
Wirksamkeitsendpunkten 
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6 Safety 
6.1 Outcomes 
The claimed benefit of leadless pacemakers in comparison to conventional 
pacemakers is the avoidance of complications associated with the surgical 
generator pocket or with the leads. In particular local complications such as 
hematoma, skin breakdown or pocket infection, as well as lead failures and 
venous obstruction due to long term transvenous implantation can be ruled 
out using leadless pacemakers.  
However complications related to the transvenous implantation procedure 
(cardiac tamponade, pneumothorax, device dislodgement) are a safety concern 
with leadless pacemakers. The implantation of leadless pacemakers uses a dif-
ferent approach than that used for transvenous leads and requires substan-
tially larger venous access tools. There were two halts to the Nanostim™ tri-
als in 2014 and 2015, due to reports of serious adverse events, including per-
foration of the heart and dislodgement of the device. 
Therefore, the following outcomes were defined as crucial to derive  
a recommendation: 
 Complication rates  
 Serious Adverse Effect (SAE) 
 Adverse device effect (ADE) 
 Serious adverse device effect (SADE) 
 Mortality (Overall and procedure-related) 
In accordance with the EC guidelines on serious adverse event reporting of 
medical devices
3
 these outcomes are defined as follows:  
Serious Adverse Event (SAE) is an adverse event that led to a death, to a seri-
ous deterioration in health of the subject, that either resulted in a life-threat-
ening illness or injury, or a permanent impairment of a body structure or a 
body function, or in-patient hospitalization or prolongation of existing hos-
pitalization, or in medical or surgical intervention to prevent life threatening 
illness or injury or permanent impairment to a body structure or a body func-
tion. This includes device deficiencies that might have led to a serious adverse 
event if a) suitable action had not been taken or b) intervention had not been 
made or c) if circumstances had been less fortunate. 
Adverse Device Effect (ADE) is an adverse event related to the use of an inves-
tigational medical device. First, this includes any adverse event resulting from 
insufficiencies or inadequacies in the instructions for use, the deployment, the 
implantation, the installation, the operation, or any malfunction of the inves-
tigational medical device. Second, this includes any event that is a result of a 
use error or intentional abnormal use of the investigational medical device. 
Serious Adverse Device Effect (SADE) is an adverse device effect that has re-
sulted in any of the consequences characteristic of a serious adverse event. 
 
                                                             
3
 http://ec.europa.eu/consumers/sectors/medical-
devices/files/meddev/2_7_3_en.pdf 
Sicherheit – 
entscheidungsrelevante 
Endpunkte: 
Komplikationsrate, 
Mortalität  
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6.2 Included Studies 
There are no comparative studies to assess the safety of leadless pacemakers. 
We identified five references to three prospective single arm studies (see Sec-
tion 5.2) that assessed the safety of leadless pacemakers in a total of 1,284 par-
ticipants [23-27]. Study characteristics and results of included studies are dis-
played in Table A-1 and in the evidence profile in Table 7-1. 
 
 
6.3 Results 
Mortality 
D0001 – What is the expected beneficial effect  
of leadless pacemakers on mortality? 
Leadless pacemakers are not expected to have a beneficial effect on mortality 
compared to conventional VVI pacemakers. 
Overall mortality ranged from 3 to 5%. Cardiac mortality was reported in two 
studies with 0.8% [24] and 1% [26, 27], respectively.  
D0003 – What is the effect of leadless pacemakers  
on the mortality due to causes other than cardiac arrhythmia? 
Procedural mortality was reported in all three studies. In LEADLESS I, one 
patient had a perforation during the implantation procedure, leading to cardi-
ac tamponade. He died of a massive cerebral artery ischaemic infarct five days 
later [23, 25]. Two procedure-related (but classified as non-device-related) 
deaths were reported in the LEADLESS II cohort: in one patient LCP implan-
tation was complicated by a large groin haematoma, the patient suffered fatal 
cardiac arrest 14 days later. The second subject underwent an unsuccessful LCP 
implant complicated by pericardial effusion, developed atrial fibrillation two 
days after the operation and died 8 days after the failed LCP implant [24]. In 
the Micra Transcatheter Pacemaker Study cohort, one death was adjudicated 
as related to the transcatheter implantation procedure: the patient had a pro-
longed procedure time due to a concomitant AV node ablation and end stage 
renal disease and the cause of death was perceived to be metabolic acidosis [26].  
 
Patient safety 
C0008 – How safe are leadless pacemakers in comparison  
to conventional single-chamber ventricular pacemakers? 
The rates of serious adverse device effects ranged between 4% and 6.5% in 
the three case series.  
There was one patient with cardiac injury in the LEADLESS I trial [25], eight 
in LEADLESS II [23, 24] and 11 cases in the Micra Transcatheter Pacemak-
er Study [26, 27].  
Six dislodgements were reported with the Nanostim™ device [23, 24], but 
none with the Micra™ TPS system [26, 27]. Other serious adverse events that 
were attributable either to the device or the procedure included vascular com-
plications, arrhythmia during device implantation and elevated pacing thres-
holds requiring retrieval and implantation of a new device. 
3 prospektive 
Einzelarmstudien mit 
1.284TeilnehmerInnen 
(Sicherheitskohorte) 
Mortalität 3-5 % 
kardiale Mortalität  
0,8-1 % 
vier Todesfälle im 
Zusammenhang mit 
dem Eingriff 
Komplikationsraten:  
4-6,5 % 
Safety 
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C0005 – What are the susceptible patient groups that are  
more likely to be harmed through the use of the technology? 
There are not enough data to answer this question. 
C0007 – Are leadless pacemakers and conventional single-chamber 
ventricular pacemakers associated with user-dependent harms? 
Leadless pacemakers and conventional single-chamber ventricular pacemak-
ers are associated with user-dependent harms due to the risk of serious ad-
verse events related with the implantation procedure.  
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [28] for each 
endpoint individually. Each study was rated by two independent researchers 
(AK, RE). In case of disagreement a third researcher was involved to solve the 
difference. A more detailed list of criteria applied can be found in the rec-
ommendations of the GRADE Working Group [28].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall the strength of evidence for the effectiveness and safety of leadless 
pacemakers in comparison to conventional pacemakers is very low.  
 
Qualität der Evidenz 
nach GRADE:  
sehr niedrig 
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Table 7-1: Evidence profile: efficacy and safety of Leadless pacemakers 
No of studies/ 
patients Study Design 
Estimate  
of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Efficacy 
Health related quality of life 
No data 
Exercise capacity 
No data 
Safety 
Cardiovascular Mortality 
2/1,251 Prospective single arm studies Range: 0.8-1% -14 0 0 0 Very low 
Procedure related Mortality 
3/1,284 Prospective single arm studies Range: 0.1-3% -14 0 0 0 Very low 
Complication rate (SADE) 
3/1,284 Prospective single arm studies Range: 4-6.5% -14 0 0 0 Very low 
SADE Serious adverse device effects 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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 No control group 
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8 Discussion 
Leadless pacemakers are an emergent technology for which there are only pre-
liminary results available. There are no data on the effect of leadless pacemak-
ers on symptoms or progression of cardiac arrhythmias. Currently, available 
evidence focusses on the feasibility and safety of the leadless pacemaker im-
plantation procedure. 
The results indicate that leadless pacemaker can be successfully implanted 
and sustain a low pacing threshold for several months. The complications as-
sociated with leads and generators can be avoided, but procedural morbidity 
and mortality is still a concern, and led to two halts of the Nanostim™ trials 
[29]. The reported rates of serious adverse device effects range from 4 to 6.5% 
in the three studies [23-27]. Acute complications associated with the implan-
tation procedure might be improved by a learning curve and/or special train-
ing to develop proficiency specific for the LCP implantation, in particular the 
handling of large venous sheaths and the intraprocedural positional integrity 
testing. Both manufacturers have proposed training programmes in their FDA 
submissions [30, 31]. However the extent to which the learning effect is able 
to significantly reduce acute complications remains to be demonstrated.  
The two products differ in the rates of dislocations (6 with Nanostim™ LCP 
vs. 0 with the Micra™ TCP). The differences might be due to the different fix-
ation technologies of the two products (see Table 3-2). It is recommended to 
re-assess the fixation technology of the Nanostim™ LCP.  
The available studies are non-randomised and there is no direct comparison 
of the benefit of LCP over contemporary single-chamber systems, so no de-
finitive conclusion can be drawn on the superiority or even non-inferiority of 
the new technology compared to standard therapy. Indirect comparisons with 
historical data from previous pacemaker studies are difficult, since most stud-
ies include patients with dual-chamber pacemakers or other implantable car-
diac devices, for which complication rates are considerably higher than for 
single-chamber pacemakers [9, 10, 14]. There are no data on clinical efficacy 
endpoints and, in particular, HRQoL was not assessed in the studies. It is 
unclear, if the avoidance of lead/generator complications translates in a rel-
evant benefit for the patients. In most patients receiving a traditional pace-
maker, HRQoL increases in the first year after pacemaker implantation – the 
occurrence of an inhospital adverse event however did not have any impact 
on how HRQoL was perceived 1 year after the pacemaker implantation [32]. 
In a number of patients, the implantation of a transvenous pacemaker system 
is precluded because of conditions such as compromised venous access, the 
need to preserve veins for haemodialysis, thrombosis, a history of infection, 
or the need for an indwelling venous catheter. While leadless pacemakers po-
tentially represent the only treatment alternative in these patients, it remains 
to be demonstrated that these patients are not at increased risk for complica-
tions associated with the implantation procedure. 
Finally, safety data are available only for 6 months follow-up. Battery longev-
ity of leadless pacemakers was estimated to be up to ten years, but actual lon-
gevity has not been measured and might be overestimated [33]. So far, there 
is no definitive answer how pacemaker-dependent patients can be treated af-
ter the battery expires. Retrievability of the leadless pacemaker after a pro-
longed implantation time has not been studied at later timepoints and might 
keine Daten zur 
klinischen Wirksamkeit 
LCP Implantation 
machbar, bei 
Komplikationsraten  
von 4 bis 6,5 % 
kein direkter Vergleich 
mit herkömmlichen 
Schrittmachern 
mögliche 
Therapieoption  
für Patienten mit 
Gegenanzeigen  
für herkömmliche 
Schrittmacher 
verfügbare Daten nur 
für 6 Monats-Follow-Up 
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be compromised by complete encapsulation of the devices observed in autop-
sies [34]. So far, there is no experience on the feasibility of the implantation 
of additional LCP in the heart chamber. 
Further evaluation of leadless pacemakers for long-term clinical efficacy and 
complication rates, compared with traditional pacemakers is required. If long-
term efficacy and safety can be demonstrated, leadless pacemakers may rep-
resent an alternative treatment option for a subset of patients with cardiac ar-
rhythmias. 
 
 
 
Langzeitdaten und 
Daten zu klinischer 
Wirksamkeit 
erforderlich 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove, that the assessed technology 
Leadless pacemakers is as effective but more safe than conventional VVI pace-
makers. New study results will potentially influence the effect estimate con-
siderably. 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Leadless pacemakers: Results from observational studies 
Study (acronym, ID no.) 
LEADLESS I – Evaluation of a new cardiac 
pacemaker (NCT01700244) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
Reference [23, 25] [24] [26, 27] 
Study description 
Country Czech Republic; Germany; Netherlands Australia; Canada; USA USA, Australia, Austria, Canada, Czech Republic, 
China, Denmark, France, Greece, Hungary, 
India, Italy, Japan, Malaysia, Netherlands, 
Serbia, South Africa, Spain, United Kingdom 
Sponsor St. JudeMedical St. JudeMedical Medtronic 
Intervention/Product Implantation of a leadless cardiac 
pacemaker/Nanostim™ LCP 
Implantation of a leadless cardiac 
pacemaker/Nanostim™ LCP 
Implantation of a leadless cardiac 
pacemaker/Micra™ TPS 
Comparator NA NA Dual-chamber pacemaker 
Study design Single cohort feasibility trial Single cohort safety/efficacy study. Single cohort safety/efficacy study with 
historical control 
Duration of the study December 2012 – April 2013 February 2014 – September 2015 November 2013 – May 2015 
Randomisation method None None None 
Blinding method (investigator, 
patient, outcomes assessor) 
Open label Open label Open label 
Intervention (n=) 33 300 (Primary cohort) 
526 (Full cohort) 
297 (Efficacy cohort) 
725 (Safety cohort) 
Control (n=) 0 0 0 
Population Patients indicated for VVI pacing who are not 
Pacemaker dependant 
Patients indicated for VVI(R) pacing Patients indicated for VVI(R) pacing 
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Study (acronym, ID no.) 
LEADLESS I – Evaluation of a new cardiac 
pacemaker (NCT01700244) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
Inclusion criteria Chronic atrial fibrillation with 2 or 3° AV or 
bifascicular bundle branch block (BBB block); or 
Normal sinus rhythm with 2 or 3° AV or 
BBB block and a low level of physical activity or 
short expected lifespan (but at least one year); or 
Sinus bradycardia with infrequent pauses or 
unexplained syncope with EP findings 
Chronic and/or permanent atrial fibrillation 
with 2 or 3° AV or bifascicular bundle branch 
block (BBB block), including slow ventricular 
rates (with or without medication) associated 
with atrial fibrillation; or 
Normal sinus rhythm with 2 or 3° AV or BBB 
block and a low level of physical activity or short 
expected lifespan (but at least one year); or 
Sinus bradycardia with infrequent pauses or 
unexplained syncope with EP findings; 
Class I or II indication for pacing (bradycardia 
due to atrial tachyarrhythmia, sinus node 
dysfunction, atrioventricular node dysfunction, 
or other causes) 
Exclusion criteria  Pacemaker dependent; 
 Known pacemaker syndrome, have retrograde 
VA conduction or suffer a drop in arterial blood 
pressure with the onset of ventricular 
pacing; 
 Pre-existing pacing or defibrillation leads; 
 Pre-existing pulmonary arterial (PA) 
hypertension or significant physiologically-
impairing lung disease; 
 Current implantation of an implantable 
cardioverter defibrillator (ICD) or cardiac 
resynchronization therapy (CRT); 
 Mechanical tricuspid valve prosthesis; 
 Presence of implanted vena cava filter; 
 Presence of implanted leadless cardiac 
pacemaker; 
 Hypersensitivity to <1mg of dexamethasone 
sodium phosphate; 
 life-expectancy <12m; pregnant or 
breastfeeding women 
 Pacemaker syndrome, retrograde VA 
conduction or drop in arterial blood pressure 
with the onset of ventricular pacing;  
 Pre-existing endocardial pacing or 
defibrillation leads; or 
 Pre-existing pulmonary arterial (PA) 
hypertension or significant physiologically-
impairing lung disease;  
 Current implantation of either conventional 
or subcutaneous implantable cardioverter 
defibrillator (ICD) or cardiac resynchronization 
therapy (CRT);  
 Mechanical tricuspid valve prosthesis;  
 Implanted vena cava filter;  
 Implanted leadless cardiac pacemaker;  
 Evidence of thrombosis in one of the veins 
used for access during the procedure;  
 Recent cardiovascular or peripheral vascular 
surgery within 30 days of enrolment  
 Allergic or hypersensitive to <1mg of 
dexamethasone sodium phosphate; 
 life-expectancy <12m; pregnant or 
breastfeeding women 
 Entirely pacemaker dependent (escape 
rhythm <30 bpm)* (restriction was lifted 
following review of the Early Performance 
Assessment) 
 Existing or prior pacemaker, ICD or CRT 
device implant;  
 Unstable angina pectoris, acute myocardial 
infarction within 30d,  
 Current implantation of neurostimulator or 
any other chronically implanted electronic 
device, mechanical tricuspid valve, implanted 
vena cava filter, or left ventricular assist 
device;  
 Morbidly obese;  
 Femoral venous anatomy unable for 
transcatheter procedure;  
 intolerance to device material or 
hypersensitivity to <1mg dexamethasone;  
 life-expectancy <12m; pregnant or 
breastfeeding women 
Primary outcome  
(including measurement tools 
and measurement times) 
S: Complication-free rate  
(freedom of SADE at 90 days) 
S: Complication-free rate  
(freedom of SADE) at 6 months 
E: Therapeutically acceptable pacing capture 
threshold (≤2.0 V at 0.4 msec) and a 
therapeutically acceptable sensing amplitude  
(R wave ≥5.0 mV, or a value equal to or greater 
than the value at implantation) through 6 months 
S: Freedom from major complications related 
to the Micra™ TPS and/or procedures at 6-month 
post-implant (within 183 days) 
E: Adequate pacing capture threshold at  
6 months (≤2 V at a pulse width of 0.24 ms  
and stable (increase of ≤1.5 V)) 
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Study (acronym, ID no.) 
LEADLESS I – Evaluation of a new cardiac 
pacemaker (NCT01700244) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
Secondary outcome (including 
measurement tools and 
measurement times) 
S:Implant success rate (% of subjects leaving 
the implant procedure with an implanted and 
functioning LCP device) 
E: pacemaker performance characteristics,  
LCP performance during magnet testing 
(predischarge) and 6-minute walking test  
(at 2 weeks) 
S: Non–device-related SAE during 6 months  
of follow-up. 
S: SADE and Non-device-related SAE during 
follow-up (Full cohort) 
E: Automated ventricular capture management 
(VCM) feature by comparing the percentage of 
subjects with a VCM within +0.5 V of pacing 
capture thresholds evaluated manually at 6 months 
Rate response during treadmill testing  
in a subset of subjects 
Micra™ TPS longevity estimates at 6 months, 
electrical performance, implant procedure 
ambulatory ECG monitoring, quality of life,  
and device orientation 
S: Adverse Events 
Freedom from SADE at 12 months 
Follow-up (months) 12 6 (Primary cohort) 
Mean (±SD) of 6.9±4.2 (Full cohort) 
6 
Loss to follow-up, n (%) 0 0 0 
Population characteristics 
Age (mean), y 76.5±8.4 75.7±11.6 
75.8±12.1 (Full cohort) 
75.9±10.9 (Safety cohort) 
vs. 71.1 ± 12.1 
Male, n (%) 22 (67) 193 (64.3) 
325 (61.8) (Full cohort) 
426 (58.8) (Safety cohort) 
vs. 1469 (55.1) 
Pacing indication, n (%) Permanent AF with AV block (including AF with 
slow ventricular response) 22 (67) 
Sinus rhythm with 2nd/3rd degree AV block and 
significant comorbidities 6 (18) 
Sinus bradycardia with infrequent pauses or 
unexplained syncope 5 (15) 
AF with AV block 294 (55.9) 
Sinus rhythm with high-grade AV block 46 (8.7) 
Sinus bradycardia with infrequent pauses or 
syncope 186 (35.4) (Full cohort) 
Bradycardia associated with persistent or 
permanent atrial tachyarrhythmia (64.0%) 
Sinus-node dysfunction (17.5%) 
AV block (14.8%) 
Other reasons (3.7%) 
Comorbidities  Diabetes, 143 (27.2) 
CAD, 201 (38.2) 
CHF, 82 (15.6) 
Hypertension, 420 (79.8) 
Valvular Disease, 106 (20.2) 
Diabetes, 207 (28.6) 
COPD, 90 (12.4) 
Renal dysfunction, 145 (20.0) 
CAD, 203 (28.0) 
AF, 526 (72.6) 
CHF, 123 (17.0) 
Hypertension, 570 (78.6) 
Valvular Disease, 306 (42.2) 
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Study (acronym, ID no.) 
LEADLESS I – Evaluation of a new cardiac 
pacemaker (NCT01700244) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
Outcomes 
Efficacy 
Pacing performance N/A (no threshold defined) 270/300 (90%, 95% CI 86.0-93.2) 292/297 (98.3) 
Quality of life NR NR NR 
Safety 
Implant success rate, n (%) 32 (97) 504/526 (95.8) 719/725 (99.2) 
Overall Mortality, n (%) 1 (3) 28/526 (5.3) 29/725 (4) 
Procedure-related mortality,  
n (%)  
1 (3) 2/526 (0.4) 1/725 (0.1*) 
Cardiac mortality, n (%)  NR 4/526 (0.8) 7/725 (1.0) 
Cardiac morbidity, n (%) NR NR NR 
Overall Adverse Events, n (%) NR NR NR 
Serious Adverse Events, n (%) NR NR NR 
Non-device-related SAE, n (%) NR 29/526 (5.5) NR 
Overall Adverse Device Effects 
(ADE), n (%) 
NR NR NR 
Serious Adverse Device Effects 
(SADE), n (%) 
2 (6) 34/526 (6.5) 25/725 (4.0*) 
Hospitalization, n (%) 9 (27) NR 12/725 (2.3*) 
Loss of device function, n (%) NR NR 1/725 (0.1*) 
Cardiac injury, n (%) 1 (3) 8/526 (1.5) 11/725 (1.6*) 
Device dislodgement, n (%) 0 6/526 (1.1) 0 
Elevated pacing thresholds 
requiring retrieval/ 
replacement, n (%) 
0 4/526 (0.8) 2/725 (0.3%*) 
LCP – Leadless cardiac pacemaker, IDE – Investigational device exemption; TPS – Transcatheter pacing system; NA – not applicable; NR – not reported; SAE – Serious adverse events;  
VCM – Ventricular capture management; AF – Atrial fibrillation; AV – atrioventricular; COPD Chronic obstructive pulmonary diseases; CAD – Coronary artery disease; CHF – Congestive 
Heart failure; CI – Confidence interval; ADE –Adverse device events; SADE – Serious adverse device events 
* 183days Kaplan-Meier estimates 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagree-
ment a third researcher was involved to solve the differences. A more detailed description of the criteria 
used to assess the internal validity of the individual study designs can be found in the Internal Manual 
of the LBI-HTA [35] and in the Guidelines of EUnetHTA [36-38].  
Table A-2: Risk of bias – study level (case series), see [30] 
Study 
LEADLESS I – 
Evaluation of a new 
cardiac pacemaker 
(NCT01700244) 
The LEADLESS II 
pacemaker  
IDE study 
(NCT02030418) 
Micra 
Transcatheter 
Pacing Study 
(NCT02004873) 
reference/ID [23, 25] [24] [26, 27] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated 
clearly in the abstract, introduction, or methods section? Yes Yes Yes 
Study population 
2. Are the characteristics of the participants included  
in the study described? 
Yes Yes Yes 
3. Were the cases collected in more than one centre? Yes Yes Yes 
4. Are the eligibility criteria (inclusion and exclusion 
criteria) for entry into the study explicit and appropriate? Yes Yes Yes 
5. Were participants recruited consecutively? Yes Yes Unclear 
6. Did participants enter the study at similar point in  
the disease? 
No No No 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? Yes Yes Yes 
8. Were additional interventions (co-interventions) 
clearly reported in the study? 
No No No 
Outcome measures 
9. Are the outcome measures clearly defined in the 
introduction or methods section? Yes Yes Yes 
10. Were relevant outcomes appropriately measured 
with objective and/or subjective methods? Yes Yes Yes 
11. Were outcomes measured before and after intervention? No No No 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant 
outcomes appropriate? Yes Yes Yes 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes Yes 
15. Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? No No Yes 
16. Are adverse events reported? Yes Yes Yes 
17. Are the conclusions of the study supported by results? Yes Yes Yes 
Competing interest and source of support 
18. Are both competing interest and source of support 
for the study reported? Yes Yes Yes 
Overall Risk of bias Low Low Low 
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Applicability table 
Table A-3: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The majority of study participants had chronic atrial fibrillation with AV block. A substantial number 
of participants had a pacemaker indication due to SND or AV block without AF based on individual 
factors precluding dual-chamber pacing. It is unclear if the selection of patients for VVI pacing in 
Austria results in comparable frequencies of the respective indication groups. 
Intervention In the studies, the intervention was the transcatheter implantation of one of two marketed products 
(Nanostim™ LCP and Micra™ TPS), which corresponds to the products likely to be used in Austria. 
Comparators There were no comparators. 
Outcomes The main outcomes reported in the studies were pacing performance for efficacy and complication 
rates for safety. No clinical outcomes were reported on efficacy. For safety, the reported outcomes 
are clinically relevant. 
Setting In all studies, the intervention was performed in a clinical setting, corresponding to the utilisation 
setting in Austria. Two studies were led in Europe, one in Australia, Canada and the US.  
No applicability issues are expected from the geographical setting.  
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List of ongoing studies 
There are no randomised controlled trials on leadless pacemakers registered. 
Table A-4: List of ongoing non-RCT studies on leadless pacemakers 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary  
completion date Sponsor 
NCT02030418  
The LEADLESS Pacemaker  
IDE Study (Leadless II) 
Bradycardia Device: Leadless 
Pacemaker 
None Complication-Free Rate  
Pacing thresholds and R-wave 
amplitudes within the 
therapeutic range 
June 2015 St. Jude Medical 
NCT02536118  
Micra Transcatheter Pacing 
System Post-Approval Registry 
Bradycardia Device: Micra™ 
Transcatheter Pacing 
System 
None Acute complication rate  
Long-term complication  
free survival 
August 2023 Medtronic 
NCT02004873  
Micra Transcatheter Pacing 
Study 
Class I or II Indication for 
Implantation of a Single Chamber 
Ventricular Pacemaker According 
to ACC/AHA/HRS 2001 Guidelines 
and Any National Guidelines 
Device: Micra™ 
Pacemaker Implant 
None Major Complications  
Pacing Capture Threshold 
Success 
May 2015 Medtronic 
Cardiac Rhythm 
Disease 
Management 
NCT02488681  
Micra Transcatheter Pacing 
System Continued Access Study 
Protocol 
Bradycardia Device: Micra™ 
Pacemaker Implant 
None Adverse Events November 2016 Medtronic 
NCT02051972  
The LEADLESS Observational 
Study 
Indications for VVI(R) Pacemaker Device: Implanted with 
a Nanostim™ leadless 
pacemaker system 
None Complication free-rate  June 2017 St. Jude Medical 
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Literature search strategies 
Search strategy for CRD 
Search Name: Leadless Pacemakers (MEL2016 AKis/ER) 
Search Date: 09.12.2015 
ID Search 
#1 MeSH DESCRIPTOR Pacemaker, Artificial EXPLODE ALL TREES 
#2 MeSH DESCRIPTOR Cardiac Pacing, Artificial EXPLODE ALL TREES 
#3 (pacemaker*) 
#4 #1 OR #2 OR #3 
#5 (leadless) 
#6 ((leadless OR transcatheter*) NEAR pacing) 
#7 #5 OR #6 
#8 #4 AND #7 
Total: 2 Hits 
 
 
Search strategy for Embase 
Search Name: Leadless Pacemakers (MEL2016 AKis/ER) 
Search Date: 09.12.2015 
ID Search 
#13 ‘heart pacing’/exp OR ‘artificial pacemaker’/exp OR pacemaker* OR peacemaker* OR  
‘pace-maker’ OR ‘pace-makers’ OR ‘peace-maker’ OR  
‘peace-makers’ AND (leadless OR (leadless OR  
transcatheter*) NEAR/4 pacing) 
#12 leadless OR (leadless OR transcatheter*) NEAR/4  
pacing 
#11 (leadless OR transcatheter*) NEAR/4 pacing 
#10 leadless 
#9 ‘heart pacing’/exp OR ‘artificial heart  
 pacemaker’/exp OR pacemaker* OR peacemaker* OR  
‘pace-maker’ OR ‘pace-makers’ OR ‘peace-maker’ OR  
‘peace-makers’ 
#8 ‘peace-makers’ 
#7 ‘peace-maker’ 
#6 ‘pace-makers’ 
#5 ‘pace-maker’ 
#4 peacemaker* 
#3 pacemaker*  
#2 ‘artificial heart pacemaker’/exp 
#1 ‘heart pacing’/exp  
Total: 128 Hits 
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Search strategy for Medline 
Search Name: Leadless Pacemakers (MEL2016 AKis/ER) 
Search Date: 09.12.2015 
ID Search 
#1 exp Pacemaker, Artificial/ 
#2 exp Cardiac Pacing, Artificial/ 
#3 pacemaker*.mp.  
#4 1 or 2 or 3  
#5 leadless.mp.  
#6 ((leadless or transcatheter*) adj5 pacing).mp.  
#7 5 or 6  
#8 4 and 7  
Total: 58 Hits 
 
 
Search strategy for Pubmed 
Search Name: Leadless Pacemakers (MEL2016 AKis/ER) 
Search Date: 09.12.2015 
ID Search 
#1 (Pacemaker, Artificial[MH] OR Cardiac Pacing, Artificial[MH] OR pacemaker*) AND  
(leadless OR leadless pac* OR transcatheter pac*) 
Total: 55 Hits 
 
 
Search strategy for Cochrane 
Search Name: Leadless Pacemakers (MEL2016 (AK/RE) 
Search Date: 09.12.2015 
ID Search 
#1 MeSH descriptor: [Pacemaker, Artificial] explode all trees 
#2 MeSH descriptor: [Cardiac Pacing, Artificial] explode all trees 
#3 (pacemaker*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 (leadless OR transcatheter*) near pacing (Word variations have been searched) 
#6 leadless (Word variations have been searched) 
#7 #5 or #6 
#8 #4 and #7 
Total: 2 Hits 
 
